| |
| |
|
| Insider
Information: |
Davis Stephen |
| Relationship: |
Director |
| City: |
Branford |
| State: |
CT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
344,117 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,595,864 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
344,117 |
|
|
| Total
Value |
$2,595,864 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
16
|
|
Stock
price went up :
|
0
|
7
|
| Stock
price went down : |
0
|
9
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -98.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Heron Therapeutics Inc |
HRTX |
Director |
2022-12-16 |
52,032 |
2010-02-17 |
0 |
Premium* |
|
|
Ardea Biosciences Inc |
RDEA |
EVP & COO |
2012-06-19 |
0 |
2010-04-06 |
0 |
Premium* |
|
|
Furiex Pharmaceuticals, Inc. |
FURX |
Director |
2014-07-02 |
0 |
2013-05-24 |
0 |
Premium* |
|
|
Acadia Pharmaceuticals Inc |
ACAD |
|
2024-05-02 |
155,231 |
2019-10-09 |
0 |
Premium* |
|
|
Bellicum Pharmaceuticals, Inc |
BLCM |
Director |
2023-01-03 |
136,854 |
2022-01-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2019-10-15 |
4 |
S |
$39.65 |
$118,276 |
D/D |
(2,983) |
2,954 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2020-04-30 |
4 |
S |
$49.21 |
$333,152 |
D/D |
(6,770) |
11,809 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2020-10-16 |
4 |
S |
$42.56 |
$125,978 |
D/D |
(2,960) |
14,786 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2021-01-06 |
4 |
S |
$53.34 |
$185,837 |
D/D |
(3,484) |
24,482 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2021-02-04 |
4 |
S |
$50.61 |
$718,409 |
D/D |
(14,195) |
28,900 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2021-04-30 |
4 |
S |
$20.33 |
$159,591 |
D/D |
(7,850) |
49,312 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2021-10-18 |
4 |
S |
$17.41 |
$51,586 |
D/D |
(2,963) |
52,906 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2022-01-06 |
4 |
S |
$23.05 |
$85,700 |
D/D |
(3,718) |
58,716 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2022-02-23 |
4 |
S |
$23.80 |
$93,486 |
D/D |
(3,928) |
65,733 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2022-05-02 |
4 |
S |
$18.18 |
$99,691 |
D/D |
(5,483) |
75,875 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2022-10-15 |
4 |
S |
$15.81 |
$44,331 |
D/D |
(2,804) |
79,009 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2023-01-09 |
4 |
S |
$17.13 |
$66,877 |
D/D |
(3,904) |
84,633 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2023-02-24 |
4 |
S |
$18.78 |
$72,322 |
D/D |
(3,851) |
91,727 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2023-04-06 |
4 |
S |
$18.16 |
$155,849 |
D/D |
(8,582) |
100,478 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2023-05-01 |
4 |
S |
$21.18 |
$165,331 |
D/D |
(7,806) |
108,297 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2023-10-06 |
4 |
S |
$21.96 |
$1,132,323 |
D/D |
(51,563) |
89,131 |
0 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2024-01-08 |
4 |
S |
$29.96 |
$111,811 |
D/D |
(3,732) |
96,521 |
0 |
% |
|
| HRTX |
Heron Therapeutics Inc |
Director |
– • – |
2014-09-26 |
4 |
OE |
$7.20 |
$866,254 |
D/D |
120,313 |
122,710 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2019-10-09 |
4 |
OE |
$19.65 |
$585,413 |
D/D |
29,792 |
29,792 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2019-10-10 |
4 |
OE |
$19.65 |
$2,362,087 |
D/D |
120,208 |
120,208 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2019-10-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,937 |
5,937 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2019-12-05 |
4 |
OE |
$19.65 |
$2,947,500 |
D/D |
150,000 |
152,954 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2020-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,625 |
18,579 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2020-05-13 |
4 |
OE |
$19.65 |
$2,190,150 |
D/D |
111,458 |
123,267 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
CEO |
• • – |
2020-05-14 |
4 |
OE |
$19.65 |
$1,739,850 |
D/D |
88,542 |
100,351 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
